A team at Berrybio (Shanghai) Ltd. has prepared proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to focal adhesion kinase (FAK)-targeting moiety through a linker.
Beigene Ltd. has disclosed new Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) inhibitors reported to be useful for the treatment of cancer, viral infections, age-related issues, neurological, immunological and inflammatory disorders.
Researchers at Suzhou Vigonvita Life Sciences Co. Ltd. have identified N-substituted quinolinones and their prodrugs acting as 5-HT1A and dopamine D3 receptor (DRD3) agonists, 5-HT2A and dopamine D2 receptor antagonists and serotonin transporter (SERT) inhibitors.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
A Hangzhou Highlightll Pharmaceutical Co. Ltd. patent describes new NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammation, liver and metabolic disease, neuroinflammation, immunological, cardiovascular and renal disorders.
Yiteng Pharmaceutical Industry (Taizhou) Co. Ltd. has disclosed new inhibitors of cyclin-dependent kinase (CDK), particularly CDK7, reported to be useful for the treatment of cancer.
Indolinone derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors are detailed in a recent Chengdu Baiyu Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.
FL2022-001 Inc. has patented new 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of liver fibrosis and nonalcoholic steatohepatitis.
Work at Praxis Precision Medicines Inc. has led to the identification of new compounds comprising an azaspiroheptane and acting as T-type calcium channel blockers, particularly voltage-dependent T-type calcium channel subunit α-1G (Cav3.1) blockers. As such, they are reported to be useful for the treatment of essential tremor.
Cognito Therapeutics Inc. is seeking patent protection for methods for measuring parameters, particularly gamma waveforms, of neurological disorders including neurodevelopmental disorders, psychiatric disorders, and neurodegenerative disorders.
RSS
